SCHEMBL4628142

SCHEMBL4628142

CC(C)(Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1OC(C)(C)C(=O)O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 7/20 0.54
MAPT P10636 3/20 0.54
MEN1 O00255 2/20 0.54
CYP3A4 P08684 2/20 0.54
KMT2A Q03164 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C19 P33261 1/20 0.54
PTGDR2 Q9Y5Y4 3/20 0.49
PPARG P37231 5/20 0.48
FABP2 P12104 2/20 0.48
SLC22A12 Q96S37 1/20 0.48
TDP1 Q9NUW8 2/20 0.43
TSHR P16473 1/20 0.43
PPARD Q03181 5/20 0.43
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4626387 0.91 MAPT (0.60) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL581884 0.82 PPARA (0.59) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL7978183 0.81 PPARA (0.57) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL1331593 0.81 PPARA (0.57) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL1369354 0.79 PPARA (0.56) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL1417566 0.79 PPARA (0.56) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL1116813 0.78 PPARA (0.54) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL1332622 0.77 PPARA (0.53) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL11285273 0.77 PPARA (0.53) PPARAMAPTMEN1CYP3A4KMT2A
SCHEMBL16358094 0.76 PPARA (0.51) PPARAMAPTMEN1CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312322-A1 Organic Compounds NOVARTIS AG (CH) 2008-12-18 US claimed
EP-1888505-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2008-02-20 EP claimed
WO-2006125593-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-11-30 WO claimed
US-20080312322-A1 Organic Compounds NOVARTIS AG (CH) 2008-12-18 US disclosed
EP-1888505-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2008-02-20 EP disclosed
WO-2006125593-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312322-A1 Organic Compounds NR3C2, MRGPRX2, HRH2 PPARA 1086/4885MAPT 4232/4885MEN1 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.